IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.466
EU - Europa 2.945
AS - Asia 1.968
OC - Oceania 15
SA - Sud America 14
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 41.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.433
SG - Singapore 1.095
CN - Cina 610
IT - Italia 504
IE - Irlanda 489
DE - Germania 416
UA - Ucraina 404
FR - Francia 343
GB - Regno Unito 183
RU - Federazione Russa 142
FI - Finlandia 127
SE - Svezia 125
KR - Corea 112
PL - Polonia 100
BE - Belgio 47
IN - India 25
UZ - Uzbekistan 24
CA - Canada 23
JP - Giappone 19
IR - Iran 16
AU - Australia 14
AT - Austria 12
ES - Italia 12
HK - Hong Kong 11
MX - Messico 10
BR - Brasile 9
VN - Vietnam 9
TH - Thailandia 8
PK - Pakistan 7
RO - Romania 7
CH - Svizzera 6
KG - Kirghizistan 6
MY - Malesia 5
EG - Egitto 4
GR - Grecia 4
ID - Indonesia 4
IL - Israele 4
NL - Olanda 4
SI - Slovenia 4
TR - Turchia 4
BD - Bangladesh 3
CL - Cile 3
CZ - Repubblica Ceca 3
EU - Europa 3
PH - Filippine 3
BG - Bulgaria 2
DK - Danimarca 2
HR - Croazia 2
HU - Ungheria 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BJ - Benin 1
EC - Ecuador 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 41.418
Salva come PNG Salva come JPEG
Città #
Wilmington 10.065
Woodbridge 9.292
Houston 9.115
Fairfield 1.283
Ann Arbor 981
Singapore 966
Chandler 799
Ashburn 607
Seattle 499
Cambridge 436
Dublin 424
Medford 330
Jacksonville 320
Santa Clara 248
New York 215
Beijing 163
Rome 159
Zhengzhou 159
Lawrence 156
Dearborn 132
Kraków 94
Moscow 84
San Diego 77
Redwood City 63
Menlo Park 59
Brussels 44
Nanjing 44
Seoul 41
Shanghai 40
Milan 39
Boardman 38
Chengdu 30
Norwalk 30
London 29
Los Angeles 28
Palo Alto 28
Hefei 26
Mülheim 25
Helsinki 24
Shenzhen 22
Falls Church 20
Mountain View 20
Lappeenranta 19
Esslingen am Neckar 17
San Mateo 17
Council Bluffs 16
Toronto 15
Munich 14
Augusta 13
Nuremberg 13
Verona 13
Bassano del Grappa 12
Guangzhou 12
Kunming 12
Bologna 10
Chicago 10
Del Norte 10
Jinan 10
Saint Petersburg 10
Ardabil 9
Center 9
Detroit 9
Kilburn 9
Las Vegas 9
Leawood 9
Wuhan 9
Hong Kong 8
Nürnberg 8
Phoenix 8
Scottsdale 8
Changsha 7
Dong Ket 7
Engelhard 7
Espoo 7
Padova 7
San Francisco 7
St. George 7
Hounslow 6
Mexico City 6
Nanchang 6
Peshawar 6
Redmond 6
Sydney 6
Indiana 5
Messina 5
Saint Louis 5
Shenyang 5
Tokyo 5
Acton 4
Auburn Hills 4
Aversa 4
Bangkok 4
Brisbane 4
Durham 4
Fuzhou 4
Napoli 4
Nottingham 4
Perugia 4
Pune 4
Sedico 4
Totale 37.730
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of infliximab in psoriatic patients over the age of 65 500
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 487
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 463
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 457
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 447
Complement and autoimmunity 443
Vasculitides and the Complement System: a Comprehensive Review 437
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 432
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 432
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 431
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 429
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 422
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 419
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 418
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 416
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 415
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 411
Apremilast for the treatment of psoriasis. 411
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 410
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 410
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 408
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 407
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 406
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 406
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 406
The significance of the development of antinuclear antibodies during infliximab treatment 404
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 398
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 398
Autoantibodies in inflammatory arthritis 398
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 397
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 392
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 392
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 390
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 389
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 386
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 385
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 385
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 384
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 383
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 383
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 383
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 382
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 382
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 382
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 382
IL-21 in the pathogenesis and treatment of skin diseases 379
Auto-reactions, autoimmunity and psoriatic arthritis 377
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 374
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 371
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 371
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 370
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 369
The interplay between inflammation and metabolism in rheumatoid arthritis 368
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 366
Skin reaction associated with chrysotherapy: an unusual case 364
Insights on the role of physical activity in patients with rheumatoid arthritis 363
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 361
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 359
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 357
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 356
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 355
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 354
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 352
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 348
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 345
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 342
Small molecule therapy for managing moderate to severe psoriatic arthritis 340
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 339
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 337
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 334
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 332
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 331
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 327
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 323
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 317
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 315
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 315
Tofacitinib for the treatment of moderate-to-severe psoriasis 314
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 312
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 303
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 299
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 297
Treatment of Hailey-Hailey disease with topical calcitriol 296
Histopathology of the skin in rheumatic diseases 296
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 292
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 292
Hereditary angioedema and autoimmunity 288
null 287
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 280
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 278
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 277
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 276
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 271
Challenges in the treatment of Rheumatoid Arthritis 257
Interaction between microbiome and host genetics in psoriatic arthritis 235
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 224
Complement, infection, and autoimmunity 222
Successful treatment of psoriatic crumbly nails with ustekinumab 211
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 200
Enteropathic spondyloarthritis: Results from a large nationwide database analysis 187
Totale 35.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.744 0 0 0 912 848 1.295 977 1.042 1.069 1.066 758 777
2020/20218.098 778 962 925 956 894 873 1.029 839 307 210 260 65
2021/20221.716 95 197 160 89 50 86 86 87 97 124 173 472
2022/20232.058 211 177 88 256 188 463 172 135 184 42 104 38
2023/20241.085 95 30 36 28 132 272 43 147 58 20 54 170
2024/20252.104 184 1.216 641 63 0 0 0 0 0 0 0 0
Totale 42.308